Investigational drug · Phase 3
HSK44459
Not approved by FDA. In 9 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Psoriasis, Idiopathic Pulmonary Fibrosis (IPF), Progressive Pulmonary Fibrosis.
Phase 3Last checked: Nov 19, 2026Latest source record: Jun 8, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
9
8 still active
All registered trials
10
Any phase or sponsor naming "HSK44459"
First trial start
2025
Jan 17, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HSK44459", any sponsor or status.
Conditions studied
As listed on its trial records.
- Psoriasis
- Idiopathic Pulmonary Fibrosis (IPF)
- Progressive Pulmonary Fibrosis
- IPF
- Bechet's Disease
- Atopic Dermatitis (AD)
- Behcet's Disease
- Idiopathic Pulmonary Fibrosis
Approved drugs for the same conditions: Atopic dermatitis (eczema) · Idiopathic pulmonary fibrosis · Immunology and inflammation · Respiratory · Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "HSK44459" as an intervention, largest first.
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of HSK44459 Tablets in Patients With Idiopathic Pulmonary FibrosisPivotal-lookingNot yet recruiting
Haisco Pharmaceutical Group Co., Ltd.Industry
NCT07519070 · 420 participants (planned) · Start Apr 5, 2026 · Primary completion Apr 5, 2028
Drug: HSK44459; HSK44459 and 4 more · For: IPF
- Evaluating the Efficacy and Safety of of HSK44459 in People With Progressive Pulmonary FibrosisPivotal-lookingNot yet recruiting
Haisco Pharmaceutical Group Co., Ltd.Industry
NCT07503587 · 378 participants (planned) · Start Apr 5, 2026 · Primary completion Dec 30, 2028
Drug: HSK44459; Placebo · For: Progressive Pulmonary Fibrosis
- Evaluating the Efficacy and Safety of of HSK44459 in People With Idiopathic Pulmonary FibrosisPivotal-lookingCompleted
Haisco Pharmaceutical Group Co., Ltd.Industry
NCT06764862 · 186 participants · Start Jan 17, 2025 · Primary completion Feb 12, 2026
Drug: HSK44459 dose 1; HSK44459 dose 2 and 2 more · For: Idiopathic Pulmonary Fibrosis
Sites: Beijing, China
- Trial of HSK44459 Cream for the Management Plaque PsoriasisPivotal-lookingActive, not recruiting
Haisco Pharmaceutical Group Co., Ltd.Industry
NCT07623486 · 180 participants (planned) · Start May 22, 2026 · Primary completion Mar 2027
Drug: HSK44459 Cream; Vehicle · For: Psoriasis
Sites: Hangzhou, China
- A Study for HSK44459 in Participants With Atopic DermatitisPivotal-lookingActive, not recruiting
Xizang Haisco Pharmaceutical Co., LtdIndustry
NCT06996912 · 150 participants (planned) · Start May 22, 2025 · Primary completion Jan 20, 2026
Drug: HSK44459; Placebo · For: Atopic Dermatitis (AD)
Sites: Jinan, China
- A Phase II Efficacy and Safety Study of HSK44459 in Subjects With Moderate to Severe Plaque PsoriasisPivotal-lookingNot yet recruiting
Haisco Pharmaceutical Group Co., Ltd.Industry
NCT07150988 · 150 participants (planned) · Start Sep 26, 2025 · Primary completion Nov 6, 2026
Drug: HSK44459 dose level 1; HSK44459 dose level 2 and 1 more · For: Psoriasis
Sites: Hangzhou, China
- Long-term Safety and Efficacy Study of HSK44459 Tablets in Patients With Idiopathic Pulmonary Fibrosis (IPF)Not yet recruiting
Haisco Pharmaceutical Group Co., Ltd.Industry
NCT07019090 · 120 participants (planned) · Start Jun 27, 2025 · Primary completion Oct 31, 2026
Drug: HSK44459 · For: Idiopathic Pulmonary Fibrosis (IPF)
- Evaluating the Efficacy and Safety of of HSK44459 in Patients With Behçet's DiseasePivotal-lookingNot yet recruiting
Haisco Pharmaceutical Group Co., Ltd.Industry
NCT06902428 · 120 participants (planned) · Start Mar 24, 2025 · Primary completion Jun 5, 2026
Drug: HSK44459; Placebo · For: Behcet's Disease
Haisco Pharmaceutical Group Co., Ltd.Industry
NCT07070739 · 120 participants (planned) · Start Jul 2025 · Primary completion Jul 2027
Drug: HSK44459 tablets · For: Bechet's Disease
Haisco Pharmaceutical Group Co., Ltd.Industry
NCT06858657 · 82 participants · Start Aug 17, 2024 · Primary completion Nov 18, 2024
Drug: HSK44459; placebo · For: Healthy
Sites: Nanjing, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Psoriasis
- TQH3906Phase 34 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Psoriasis, Systemic Lupus Erythematosus, Psoriatic Arthritis
- AK111Phase 32 trials
Akeso · Psoriasis, Skin Diseases, Ankylosing Spondylitis
- IBI112Phase 32 trials
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. · Psoriasis
- Blinded EnvudeucitinibPhase 31 trial
Alumis Inc · Plaque Psoriasis, Psoriasis (PsO), Psoriasis
- CMAB015Phase 31 trial
Taizhou Mabtech Pharmaceutical Co.,Ltd · Psoriasis
- HPP737Phase 31 trial
Newsoara Biopharma Co., Ltd. · Psoriasis
- LZM012Phase 31 trial
Livzon Pharmaceutical Group Inc. · Psoriasis
- Open-Label EnvudeucitinibPhase 31 trial
Alumis Inc · Plaque Psoriasis, Psoriasis (PsO), Psoriasis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.